Novo Nordisk: CagriSema, Price Cuts, and the End of Pipeline Superiority?

Novo Nordisk built the modern obesity pharmacology market. The Danish company turned semaglutide from a diabetes treatment into a cultural phenomenon, growing obesity care sales from DKK 6 billion in 2019 to DKK 82 billion in 2025. Then, in the space of ten days in February, the narrative collapsed. CagriSema — Novo's next-generation combination drug and the single most important pipeline asset for its post-Wegovy growth story — failed to demonstrate non-inferiority on weight loss against Eli Lilly's tirzepatide in the REDEFINE 4 head-to-head trial. The stock plummeted to its lowest level since June 2021. Days later, the company announced it would slash the list prices of Wegovy and Ozempic by up to 50% starting January 2027. Then Goldman Sachs downgraded the stock to neutral.

The financial picture is complicated by the fact that Novo's Q4 2025 results actually beat expectations. EPS came in at $1.02 against a forecast of $0.92, and revenue reached $12.53 billion versus $11.99 billion expected. Full-year 2025 delivered 10% sales growth and 6% operating profit growth at constant exchange rates. But the 2026 outlook landed like a cold shower: adjusted sales and operating profit are both expected to decline between 5% and 13% at constant exchange rates. Gross margins compressed from 84.7% to 81.0%, signalling that pricing pressure is not a future risk but a present reality. The market sold the stock down nearly 15% on the earnings print despite the beat, because the forward trajectory — not the backward snapshot — is what matters.

Bears see a company losing on three fronts simultaneously. CagriSema delivered 23.0% weight loss after 84 weeks versus 25.5% for tirzepatide, undermining the pipeline superiority thesis that justified a premium multiple. Goldman Sachs cut peak sales expectations for CagriSema and cagrilintide monotherapy from approximately $11.8 billion to $5.2 billion, with obesity peak sales alone falling from $7.5 billion to $3 billion. Meanwhile, Eli Lilly's oral GLP-1, orforglipron, is expected to receive an FDA decision as soon as Q2 2026, giving Novo's newly launched Wegovy pill only a few months of head start.

Bulls see a company trading at roughly 10x forward earnings, generating over DKK 35 billion in annual free cash flow, and making a deliberate bet that volume growth at lower prices will more than offset margin compression. The Wegovy pill launch has shown strong early uptake with approximately 50,000 weekly prescriptions. Medicare will start covering obesity drugs for some patients for the first time in mid-2026, a move that could unlock 20 to 30 million eligible beneficiaries. CEO Mike Doustdar framed the price reductions as an investment, not a retreat. The catalyst window is compressed. CagriSema's FDA decision is anticipated by late 2026. Lilly's orforglipron could be approved as soon as Q2 2026. Every quarter between now and then forces the market to re-evaluate whether Novo is executing a credible transition or watching its competitive position erode in real time.

Participation Opportunity

Woozle Research is inviting professional investors to sponsor or co-sponsor this primary research. All funds receive full access to research outputs including interview summaries, transcripts, and the final synthesis report. Email sales@woozleresearch.com for more information.

This research will proceed with a minimum of one fund and is limited to a maximum of five.

Key Insights

CagriSema's failure to match tirzepatide has fundamentally repriced the pipeline. Goldman Sachs reduced combined CagriSema and cagrilintide monotherapy sales estimates by approximately 65% across its forecast horizon following the REDEFINE 4 result. The trial was open-label, and Novo's Chief Scientific Officer Martin Holst Lange argued this design can introduce bias in favour of a well-known product. That nuance has not persuaded the market. Goldman analyst James Quigley described the stock as a "show-me story" that could hold back performance.

Novo is guiding for its first year of declining sales and profits in the GLP-1 era. In Q4 2025, sales declined 2% and operating profit fell 4% at constant exchange rates. The 2026 outlook calls for sales and operating profit to decline between 5% and 13% at CER on an adjusted basis. Management is explicitly absorbing margin compression to defend and expand market share. This is not a temporary blip.

The Wegovy pill is the most important near-term commercial variable. Novo launched the Wegovy pill in the US on January 5, with early demand of approximately 50,000 prescriptions in the week ending January 23 — roughly 45,000 of which were self-pay — and availability at over 70,000 pharmacies. Whether Novo can sustain that momentum once Lilly's oral product enters the market is the central commercial question.

The pricing war is accelerating faster than most models anticipated. Wegovy and Ozempic will see their list prices cut to $675 per month from January 2027, representing a 50% reduction for Wegovy from its current list price of approximately $1,350. Under the government deal, Medicare and Medicaid prices drop to $245 per month. The bull thesis requires that volume growth at these price points more than offsets the revenue-per-patient decline.

Eli Lilly's competitive position has strengthened on every dimension. Lilly's tirzepatide-based drugs Mounjaro and Zepbound generated combined sales of $24.8 billion in the first nine months of 2025, accounting for 54% of Eli Lilly's total revenues. Lilly has built pre-launch inventories worth $1.5 billion, primarily for orforglipron, signalling an intent to launch aggressively and avoid the supply shortages that plagued early GLP-1 rollouts.

The leadership transition adds execution risk at the worst possible moment. Novo appointed Mike Doustdar as CEO and made significant board changes, followed by a restructuring programme announced in September 2025 to streamline operations. Doustdar is steering the company through a simultaneous product launch, pricing reset, pipeline setback, and competitive intensification. The market has yet to see his full strategic blueprint.

The Catalyst

Novo Nordisk's crisis is not a single data point. It is the convergence of a pipeline disappointment, a pricing revolution, and a competitive acceleration arriving at the same moment the company's first-generation franchise approaches patent expiry. Understanding which of these pressures is transient and which is structural is the central investment question.

The CagriSema disappointment cuts deepest because it strikes at the heart of Novo's long-term narrative. For three years, the bull case rested on a simple logic: even as competition intensified in the current generation of GLP-1s, Novo would leapfrog rivals with a next-generation combination drug that delivered superior efficacy. The REDEFINE 4 trial showed CagriSema 2.4 mg/2.4 mg achieved weight loss of 23.0% after 84 weeks, compared to 25.5% for tirzepatide 15 mg. The gap is not enormous in clinical terms. But the failure to meet non-inferiority means Novo cannot market CagriSema as at least as good as the Lilly drug. That distinction matters enormously in payer negotiations, formulary placement, and physician prescribing decisions.

Novo's scientific leadership has not conceded defeat. CEO Mike Doustdar maintained that CagriSema has "right now, the best weight efficacy than any product currently in the market." Chief Scientific Officer Martin Holst Lange pointed to the upcoming REDEFINE 11 trial and a planned higher-dose CagriSema study as pathways to demonstrate the drug's full potential, with REDEFINE 11 data expected in the first half of 2027 and a higher-dose trial initiation planned for the second half of 2026. But these are 12-to-18-month catalysts. The market needs answers now.

The pricing dimension compounds the pipeline problem. Novo and Lilly have escalated a GLP-1 pricing war over the last year, especially following the most favoured nation deals struck with the Trump administration in November. Lower prices unlock volume through Medicare coverage, self-pay channels, and broader payer access. But they also compress the revenue per patient that made GLP-1 franchises the highest-margin businesses in pharma. Novo still holds a 62% market volume share in GLP-1s. The question is whether that share holds at lower price points, or whether Lilly's superior efficacy data and imminent oral launch erode it.

The competitive timing is particularly unfavourable. Lilly expects an FDA decision on orforglipron in Q2 2026, with a national priority voucher that could significantly accelerate the agency's evaluation. As an initial therapy, orforglipron helped people with obesity lose around 12% of their body weight at the highest dose — a result that fell short of injectables, but the convenience of a daily pill without food or water restrictions, combined with Lilly's $1.5 billion pre-launch inventory and immediate Medicare coverage at launch, creates a formidable competitive threat to Novo's early Wegovy pill momentum.

The next 90 days will determine whether Novo's stock stabilises or continues its descent. Shares have fallen 27% year-to-date, and since Goldman added the stock to its buy list in May 2024, the Copenhagen-listed shares are down 74% versus the FTSE World Europe up 23%. The Q1 2026 earnings report on May 6 will be the first full quarter of Wegovy pill commercial data, the first quarter reflecting the Medicare obesity coverage ramp, and the first quarter under the new pricing architecture. It will either validate Doustdar's volume-over-price thesis or confirm the bears' view that Novo is managing a franchise in structural decline.

Key Intelligence Questions

The research will focus on the commercial and clinical dynamics that determine whether Novo Nordisk's competitive position in obesity and diabetes is experiencing a cyclical reset or a permanent narrowing.

Prescriber Behaviour: Does the CagriSema Result Change How Physicians Choose?

The REDEFINE 4 trial result sits in a clinically ambiguous zone. A 2.5 percentage point difference in weight loss between CagriSema and tirzepatide is statistically meaningful for a non-inferiority endpoint but may or may not change prescribing behaviour in practice. Physicians do not prescribe from clinical trial abstracts alone. They weigh tolerability, titration flexibility, patient adherence, insurance coverage, and their own accumulated clinical experience with a molecule.

The bear case assumes the result is a knockout blow — that payers use the data to favour Lilly's formulary placement and Novo loses its ability to position CagriSema as a best-in-class next-generation therapy. The bull case is that prescribers are pragmatic. They have years of experience with semaglutide, they trust its safety profile, and many patients are already stable on Wegovy or Ozempic. CagriSema, even at 23% weight loss, would still represent a meaningful step up from current semaglutide monotherapy. How obesity medicine specialists, endocrinologists, and primary care physicians in the US and EU are interpreting the REDEFINE 4 data is not something public filings can reveal.

Key Intelligence Question: Are obesity medicine specialists and endocrinologists treating the REDEFINE 4 non-inferiority failure as a decisive negative, or as a technical result that does not change their clinical calculus? And how many are actively shifting new patient starts toward tirzepatide-based therapies on the basis of this single readout?

Wegovy Pill Trajectory: Is Early Momentum Sustainable or a Self-Pay Sugar Rush?

The Wegovy pill launch generated approximately 50,000 weekly prescriptions within its first weeks, with roughly 45,000 of those coming from self-pay patients. That ratio is remarkable. It suggests that the early adopter cohort is overwhelmingly cash-pay — patients who want the convenience of a pill and are willing to pay out of pocket before commercial insurance coverage catches up. The question is what happens when the self-pay wave plateaus and the drug must compete for formulary-covered lives.

Commercial payers have been slow to add obesity coverage. Medicare coverage begins mid-year but at significantly lower reimbursement levels. And Lilly's orforglipron, if approved in Q2, will immediately enter as a direct competitor in the oral obesity space. The Wegovy pill's early prescription numbers look impressive against injectable launch benchmarks, but the comparison may be misleading if the oral market has fundamentally different adoption dynamics. Real-time refill data from retail pharmacy and telehealth channels is the only way to assess whether early momentum is converting into durable patient retention.

Key Intelligence Question: What does the prescription refill curve look like after the first two months of the Wegovy pill launch, and are patients converting from self-pay to insured coverage or dropping off — and how does that trajectory change once Lilly's oral product enters the market?

Payer and Formulary Dynamics: Who Wins the Contracting War at Lower Prices?

The GLP-1 pricing landscape is being rewritten in real time. Medicare and Medicaid prices for both Novo's and Lilly's drugs are converging at $245 per month. Novo is cutting list prices to $675 per month starting January 2027. When prices converge, the basis of competition shifts from affordability to clinical differentiation and contracting leverage. This is where the CagriSema data could matter most. If Lilly can point to superior head-to-head efficacy data in payer negotiations, it can extract preferential formulary positioning, step-therapy protocols that favour tirzepatide, and exclusive or near-exclusive contracts with large employers and health plans.

Novo's contracting leverage historically rested on being the first mover with the deepest clinical evidence base. That advantage is eroding. Pharmacy benefit manager formulary directors at Express Scripts, CVS Caremark, and Optum Rx are the critical interview targets. The question is whether Novo's contracting position has weakened following the REDEFINE 4 readout, or whether payers still value having two strong GLP-1 suppliers to maintain pricing competition.

Key Intelligence Question: Has the REDEFINE 4 result materially shifted Novo's contracting leverage with major PBMs and commercial payers — and are formulary directors using the efficacy gap to extract preferential positioning for tirzepatide-based products in 2026 and 2027 plan year negotiations?

Medicare Volume Unlock: How Fast Does the Obesity Market Expand Under Coverage?

Medicare will start covering obesity drugs for some patients for the first time in mid-2026. This is the single largest potential demand catalyst in the GLP-1 market's history. Lilly's CEO estimates 20 to 30 million Medicare beneficiaries could be eligible. But eligibility does not equal uptake. The programme is being implemented as a pilot covering a majority of Part D beneficiaries, not a universal benefit. Administrative complexity, prior authorisation requirements, and physician awareness will all shape the speed of adoption.

The bull case for Novo rests heavily on this catalyst. If Medicare volume scales rapidly, even lower per-patient revenue can produce aggregate growth. If adoption is slow, bureaucratic, or disproportionately captured by Lilly's products, the volume thesis collapses. This is especially relevant given that Lilly's orforglipron launch timing appears designed to coincide with Medicare coverage activation. Medicare Part D plan medical directors, geriatric medicine specialists, and pharmacy directors at integrated health systems are the only sources who can clarify how this is actually being operationalised.

Key Intelligence Question: How are Medicare Part D plans operationalising obesity drug coverage — what prior authorisation barriers exist, how are plans choosing between Novo and Lilly products on formulary, and what is the realistic pace of eligible patient uptake in the first two quarters of coverage?

Competitive Escalation: Can Novo Defend Share Against Lilly's Oral and Injectable Offensive?

Lilly's tirzepatide franchise generated $24.8 billion in the first nine months of 2025 alone. The company has stockpiled $1.5 billion in pre-launch inventory for orforglipron. In the ACHIEVE-3 trial, orforglipron outperformed oral semaglutide across primary and all key secondary endpoints in type 2 diabetes. Lilly is not merely competing — it is executing a coordinated offensive across injectables, orals, diabetes, and obesity simultaneously.

Novo's defence rests on its incumbency, its manufacturing scale, its physician relationships, and the early lead of the Wegovy pill. The company maintains a 62% market volume share in GLP-1s. But share is a lagging indicator. The leading indicators are new-to-brand prescription trends, competitive win rates in formulary reviews, and the pace at which Lilly is converting Novo patients. Novo Nordisk field sales representatives and regional medical science liaisons in high-volume US markets could reveal how competitive dynamics are playing out at the physician level in real time.

Key Intelligence Question: Is Novo's market share eroding at the margin as tirzepatide gains prescriber momentum, or does the CagriSema result and Lilly's oral launch represent a genuine inflection point in competitive dynamics — and are Lilly field teams and managed care account executives becoming measurably more aggressive in their contracting approach post-REDEFINE 4?

How to Participate

Woozle Research is inviting professional investors to sponsor or co-sponsor this primary research. All funds receive full access to research outputs including interview summaries, transcripts, and the final synthesis report. Email sales@woozleresearch.com for more information.

This research will proceed with a minimum of one fund and is limited to a maximum of five.

This document is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Woozle Research conducts primary research on behalf of institutional investors. All research is conducted in compliance with applicable regulations.